💊 Obat A-Z 🧬 Target 🛠 Alat 📚 Panduan
Semua Obat Kelas Obat Area Terapeutik Efek Samping
Panduan Glosarium Linimasa
Perbandingan Perjalanan Obat Famili Obat
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Hydroquinone

CHEMBL537 Phase 4 Disetujui Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
110.1 g/mol
LogP
0.6
Phase
4

A topical skin-lightening agent used to treat hyperpigmentation conditions such as melasma, age spots, and post-inflammatory hyperpigmentation by inhibiting the enzyme tyrosinase, which is needed for melanin production in the skin. It has also been investigated for antioxidant and other biological properties in research contexts. Long-term or excessive use can paradoxically cause ochronosis, a darkening of the skin.

Berat Molekul

110,1100 g/mol

LogP

0,60

TPSA

40,50 Ų

Lipinski RO5

Lulus

Area Terapeutik

Rheumatoid Arthritis Alzheimer's Disease

Mekanisme Kerja

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Struktur 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Oc1ccc(O)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H

                

                

                

                    
                    

                        
Molecular Formula

                        
C6H6O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
Ikatan yang Dapat Dirotasi

                        
0

                    

                    
                    
                    

                        
Atom Berat

                        
8

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Pertanyaan yang Sering Diajukan

                

                    
                    

                        
                        

                            
A topical skin-lightening agent used to treat hyperpigmentation conditions such as melasma, age spots, and post-inflammatory hyperpigmentation by inhibiting the enzyme tyrosinase, which is needed for melanin production in the skin. It has also been investigated for antioxidant and other biological properties in research contexts. Long-term or excessive use can paradoxically cause ochronosis, a darkening of the skin.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Hydroquinone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL537.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 785.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Penyangkalan Medis

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.